This trial is testing a new antibody drug to see if it is effective and safe for treating mild to moderate COVID-19 in non-hospitalized high-risk patients. There is also a safety substudy to assess the safety and tolerability of a single dose of the drug.
1 Primary · 50 Secondary · Reporting Duration: up to Week 36
1200 Total Participants · 5 Treatment Groups
Primary Treatment: VIR-7831 sotrovimab · No Placebo Group · Phase 3
Age Any Age · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||75.0%|
|Did not meet criteria||50.0%|